Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

被引：1

作者：

Sodre, Andressa L.

Woods, David M.

Sarnaik, Amod

Betts, Brian C.

Quayle, Steven

Jones, Simon

Weber, Jeffrey

机构：

来源：

CANCER RESEARCH | 2017年 / 77卷

关键词：

D O I：

10.1158/1538-7445.AM2017-638

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

638

引用

页数：2

共 50 条

[21] The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity
Mathew, Rebecca
Haribhai, Dipica
Kohlhapp, Fred
Duggan, Ryan
Ellis, Paul
Riehm, Jacob J.
Robinson, Valerie A.
Shi, Yan Y.
Bhathena, Anahita
Leverson, Joel D.
Pappano, William N.
Donawho, Cherrie K.
Uziel, Tamar
BLOOD, 2018, 132
[22] Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells
Satoh, Kazuki
Kobayashi, Yoichi
Fujimaki, Kaori
Hayashi, Shinko
Ishida, Saori
Sugiyama, Daisuke
Sato, Takahiko
Lim, Kyungtaek
Miyamoto, Megumi
Kozuma, Shiho
Kadokura, Michinori
Wakita, Kenichi
Hata, Masato
Hirahara, Kazuki
Amano, Masato
Watanabe, Ichiro
Okamoto, Atsushi
Tuettenberg, Andrea
Jonuleit, Helmut
Tanemura, Atsushi
Maruyama, Shoichi
Agatsuma, Toshinori
Wada, Teiji
Nishikawa, Hiroyoshi
INTERNATIONAL IMMUNOLOGY, 2021, 33 (08) : 435 - 446
[23] EGFR inhibition augments anti-tumor immune responses by HER family-specific human CD4 helper T cells in vitro.
Kumai, Takumi
Harabuchi, Yasuaki
Kobayashi, Hiroya
CANCER RESEARCH, 2013, 73 (08)
[24] Interferon-alpha boosts anti-tumor immunity through effects on T cells and dendritic cells and augments the clinical efficacy of regulatory T cell depletion
Wall, Shawna
Thibodeaux, Suzanne
Daniel, Benjamin
Jeansonne, Duane
Sun, Xiuhua
Ludwig, Sara
Lomada, Dakshayani
Kious, Mark
Curiel, Tyler J.
CYTOKINE, 2009, 48 (1-2) : 8 - 8
[25] Bexarotene activates type 1 antigen presenting cells, increases tumor infiltrating CD8 T-cells, and augments the anti-tumor activity of chemotherapy in breast cancer
Stanton, Sasha Elizabeth
Gad, Ekram
Corulli-Rastetter, Lauren R.
Disis, Mary L.
CANCER RESEARCH, 2017, 77
[26] TRP-1 reactive BiTE proteins and CAR T-cells engage different anti-tumor immune mechanisms
Shivde, R.
Marx, N.
Gacek, S.
Dhiantravan, S.
Balyasnikova, I.
Le Poole, I.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S111 - S111
[27] HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells
Oliveira, Leilane Sales
Oliveira-Silva, Joao Marcos
Almeida-Souza, Hebreia Oliveira
Martins, Mario Machado
Chiminazo, Carolina Berraut
Fonseca, Rafael
de Souza, Carlos Vinicius Expedito
Aissa, Alexandre Ferro
Bastos, Luciana Machado
Ionta, Marisa
Lima, Graziela Domingues de Almeida
Castro-Gamero, Angel Mauricio
INVESTIGATIONAL NEW DRUGS, 2025, : 223 - 242
[28] Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells (Vol 39, 100893, 2023)
Shui, Yifang
Hu, Xin
Hirano, Hiroshi
Tsukamoto, Hirotake
Guo, Wen-Zhi
Hasumi, Kenichiro
Ijima, Fumihiro
Fujino, Masayuki
Li, Xiao-Kang
NEOPLASIA, 2024, 55
[29] Disruption of STAT3 signaling in CLL B cells through HDAC6 inhibition reverses CLL T-cell exhaustion
Maharaj, Kamira
Powers, John
Achille, Alex
Nieto, Adrian
Sahakian, Eva
Pinilla-Ibarz, Javier
LEUKEMIA & LYMPHOMA, 2020, 61 : 50 - 50
[30] Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells
Baker, Forrest L.
Bigley, Austin B.
Agha, Nadia H.
Pedlar, Charles R.
O'Connor, Daniel P.
Bond, Richard A.
Bollard, Catherine M.
Katsanis, Emmanuel
Simpson, Richard J.
FRONTIERS IN IMMUNOLOGY, 2020, 10

← 1 2 3 4 5 →